Role of Janus Kinase inhibitors in the management of pulmonary involvement due to Long COVID-19 disease: A case control study
OBJECTIVES: Ongoing symptomatic coronavirus disease 2019 (OSC) is defined as persistent symptoms beyond 4 weeks of acute illness. OSC leads to prolonged hospitalization and oxygen dependence. We aimed to find the outcome of Janus kinase inhibitors (JAKi) as a steroid-sparing agent to treat OSC. METH...
Saved in:
Main Authors: | Pawan Kumar Singh, Vinod Kumar Sharma, Lokesh Kumar Lalwani, Dhruva Chaudhry, Manjunath B. Govindagoudar, Chaudhari Pramod Sriram, Aman Ahuja |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-07-01
|
Series: | Turkish Journal of Emergency Medicine |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/tjem.tjem_363_22 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study
by: Filip Van den Bosch, et al.
Published: (2025-02-01) -
Exploratory study on the efficacy of topical pan-JAK inhibitor in ocular and skin GVHD in a sclerodermatous GVHD mouse model
by: Shinri Sato, et al.
Published: (2025-01-01) -
Contents of plasma М2-pyruvate kinase (M2-РК) in patients with inflammatory bowel diseases
by: Ye. A. Konovich, et al.
Published: (2010-11-01) -
Multifunctional Janus-Structured Polytetrafluoroethylene-Carbon Nanotube-Fe3O4/MXene Membranes for Enhanced EMI Shielding and Thermal Management
by: Runze Shao, et al.
Published: (2025-02-01) -
Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?
by: Tommaso Porcelli, et al.
Published: (2025-02-01)